BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37285071)

  • 21. [Timing of surgery after neoadjuvant chemotherapy for advanced gastric cancer].
    Hu X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jun; 16(6):509-12. PubMed ID: 23801199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Timing of surgery after neoadjuvant chemotherapy for gastric cancer: Impact on outcomes.
    Liu Y; Zhang KC; Huang XH; Xi HQ; Gao YH; Liang WQ; Wang XX; Chen L
    World J Gastroenterol; 2018 Jan; 24(2):257-265. PubMed ID: 29375211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
    Cats A; Jansen EPM; van Grieken NCT; Sikorska K; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; Boot H; Trip AK; Swellengrebel HAM; van Laarhoven HWM; Putter H; van Sandick JW; van Berge Henegouwen MI; Hartgrink HH; van Tinteren H; van de Velde CJH; Verheij M;
    Lancet Oncol; 2018 May; 19(5):616-628. PubMed ID: 29650363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East.
    Fujitani K
    Dig Surg; 2013; 30(2):119-29. PubMed ID: 23867588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant radiation therapy does not increase perioperative morbidity among patients undergoing gastrectomy for gastric cancer.
    Sun Z; Nussbaum DP; Speicher PJ; Czito BG; Tyler DS; Blazer DG
    J Surg Oncol; 2015 Jul; 112(1):46-50. PubMed ID: 26179329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma: A National Cancer Data Base analysis.
    Stumpf PK; Amini A; Jones BL; Koshy M; Sher DJ; Lieu CH; Schefter TE; Goodman KA; Rusthoven CG
    Cancer; 2017 Sep; 123(17):3402-3409. PubMed ID: 28513823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Propensity Score Analysis of Chemotherapy Use in Patients With Resectable Gallbladder Cancer.
    Ozer M; Goksu SY; Sanford NN; Porembka M; Khurshid H; Ahn C; Maxwell MC; Beg MS; Kazmi SM
    JAMA Netw Open; 2022 Feb; 5(2):e2146912. PubMed ID: 35171262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postoperative Complications After Neoadjuvant Chemotherapy Versus Upfront Surgery in Gastric Adenocarcinoma: A Population-Based Nationwide Study in Finland.
    Putila E; Helminen O; Helmiö M; Huhta H; Jalkanen A; Kallio R; Koivukangas V; Kokkola A; Laine S; Lietzen E; Louhimo J; Meriläinen S; Pohjanen VM; Rantanen T; Junttila A; Ristimäki A; Räsänen JV; Saarnio J; Sihvo E; Toikkanen V; Tyrväinen T; Valtola A; Kauppila JH;
    Ann Surg Oncol; 2024 Apr; 31(4):2689-2698. PubMed ID: 38153640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.
    Wang X; Li S; Sun Y; Li K; Shen X; Xue Y; Liang P; Li G; Chen L; Zhao Q; Li G; Fu W; Liang H; Xin H; Suo J; Fang X; Zheng Z; Xu Z; Chen H; Zhou Y; He Y; Huang H; Zhu L; Yang K; Ji J; Ye Y; Zhang Z; Li F; Wang X; Tian Y; Park S; Chen L
    BMC Cancer; 2021 Jan; 21(1):20. PubMed ID: 33402102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of S-1 plus Cisplatin Neoadjuvant Chemotherapy on Scirrhous Gastric Cancer.
    Kunisaki C; Makino H; Kimura J; Takagawa R; Kanazawa A; Ota M; Kosaka T; Ono HA; Akiyama H; Endo I
    Oncology; 2015; 88(5):281-8. PubMed ID: 25591954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant Intraperitoneal and Systemic Chemotherapy Versus Neoadjuvant Systemic Chemotherapy With Docetaxel, Oxaliplatin, and S-1 for Gastric Cancer With Peritoneal Metastasis: A Propensity Score Matched Analysis.
    Zhang X; Huang H; Yang D; Wang P; Huang X; Hu Z; Zhang Y; Yan R; Zhu Z; Cai Q
    Technol Cancer Res Treat; 2021; 20():15330338211036310. PubMed ID: 34328799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does neoadjuvant/perioperative chemotherapy improve overall survival for T2N0 gastric adenocarcinoma?
    Gabriel E; Attwood K; Narayanan S; Brady M; Nurkin S; Hochwald S; Kukar M
    J Surg Oncol; 2018 Mar; 117(4):659-670. PubMed ID: 29127704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant chemotherapy
    Li Y; Ma FH; Xue LY; Tian YT
    World J Gastroenterol; 2020 Feb; 26(8):818-827. PubMed ID: 32148379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Utilization of multimodal therapy concepts in stomach carcinoma in Germany].
    Bösing NM; Heise JW; Röher HD
    Zentralbl Chir; 2000; 125(4):341-7. PubMed ID: 10829314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does hipec improve outcomes in gastric cancer patients treated with perioperative chemotherapy and radical surgery? A propensity-score matched analysis.
    Diniz TP; da Costa WL; Fonseca de Jesus VH; Ribeiro HSC; Diniz AL; de Godoy AL; de Farias IC; Torres SM; Felismino TC; Coimbra FJF
    J Surg Oncol; 2020 Apr; 121(5):823-832. PubMed ID: 31950511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Neoadjuvant Chemotherapy on Postoperative Morbidity after Gastrectomy for Gastric Cancer.
    Téoule P; Trojan J; Bechstein W; Woeste G
    Dig Surg; 2015; 32(4):229-37. PubMed ID: 25966823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
    Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
    Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer.
    Kang YK; Yook JH; Park YK; Lee JS; Kim YW; Kim JY; Ryu MH; Rha SY; Chung IJ; Kim IH; Oh SC; Park YS; Son T; Jung MR; Heo MH; Kim HK; Park C; Yoo CH; Choi JH; Zang DY; Jang YJ; Sul JY; Kim JG; Kim BS; Beom SH; Cho SH; Ryu SW; Kook MC; Ryoo BY; Kim HK; Yoo MW; Lee NS; Lee SH; Kim G; Lee Y; Lee JH; Noh SH
    J Clin Oncol; 2021 Sep; 39(26):2903-2913. PubMed ID: 34133211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Laparoscopic gastrectomy combined with neoadjuvant chemotherapy for gastric cancer patients: from the view of the CLASS-03a trial].
    Hu J; Zhang W; Chen X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Feb; 21(2):138-142. PubMed ID: 29492910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.